联合厄洛替尼治疗肺腺癌的临床研究2.docVIP

山东中医药大学2010届硕士学位论文 作者单位：250001山东 济南 山东中医药大学第二附属医院 呼吸内科 肺抑瘤合剂联合厄洛替尼治疗肺腺癌的临床研究 李家曌 郑心 李士涛 【提要】 目的 临床比较肺抑瘤合剂联合厄洛替尼治疗和单用厄洛替尼治疗中晚期肺腺癌的疗效，分析肺抑瘤合剂抗肿瘤的作用机理。方法 将70例经细胞学、病理学确诊的原发性支气管肺癌（腺型）患者采用简单随机对照方法分为联合治疗组（简称治疗组，35例）与靶向治疗组（简称对照组，35例）。治疗组采用肺抑瘤合剂联合厄洛替尼靶向治疗治疗，对照组单纯采用厄洛替尼进行靶向治疗治疗。观察两组的临床疗效。结果 临床观察显示，肺抑瘤合剂联合厄洛替尼靶向治疗在改善症状、提高生存质量、稳定病灶、减毒增效等方面均优于对照组（P0.05或P0.01）。结论 肺抑瘤合剂是一首治疗的肺癌的有效方剂，临床结果示其抑制肿瘤生长及对抗厄洛替尼靶向治疗副作用方面作用显著。 【关键词】 肺抑瘤合剂；肺腺癌；厄洛替尼 Clinical and Experimental Study on Treating Lung Cancer with Erlotinib and Fei Yiliu Heji Lee jia-zhao, Zhengxin et al Department of Respiratory, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong 【Abstract】 Objective The objectives of the present study are to evaluate the effectiveness of Erlotinib and Feiyiliuheji in treating the lung cancer of Adenocarcinoma and to discuss its mechanism in treatment. Methods The study starts with 70confirmed primary lung cancer of Adenocarcinoma patients who were randomly divided into two groups. 35 patients within the Treated Group were treated with Feiyiliuheji and Erlotinib together. The other 35 patients within the Controlled Group were treated with Erlotinib only. The clinical therapeutic effects were then observed. Results In the clinical study, the Treated Group showed better than the Controlled Group in symptom betterment, improving the quality of existence, focus stabilization and weakening cancer and enhancing the effects of treatment. Conclusions The findings indicate that Feiyiliuheji is safe and effective in the combined-modality therapy of lung cancer of Adenocarcinoma, and may be decreasing the expression of VEGF, and halting the growth, and metastasis of the carcinoma cells, and reduce the side-effection of Erlotinib. 【Key words】 Feiyiliuheji；lung cancer of Adenocarcinoma；Erlotinib 肿瘤中药治疗是药物经济学发展领域里的一个重大进步，将真正实现肿瘤患者治疗的个体化,也使得肿瘤治疗进入诊断治疗一体化的新时代，越来越多的研究表明中医药在肺癌治疗中的作用肯定。临床上Ⅲ、Ⅳ期肺腺癌患者失去手术时机，且对化疗极不敏感，疗效差，而中医药治疗在降低医疗费用、改善症状、生活质量和生存期方面有明显优势。我们共观察治